NO993979L - FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor - Google Patents

FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Info

Publication number
NO993979L
NO993979L NO993979A NO993979A NO993979L NO 993979 L NO993979 L NO 993979L NO 993979 A NO993979 A NO 993979A NO 993979 A NO993979 A NO 993979A NO 993979 L NO993979 L NO 993979L
Authority
NO
Norway
Prior art keywords
alzheimer
onset
disease
composition
procedures
Prior art date
Application number
NO993979A
Other languages
English (en)
Norwegian (no)
Other versions
NO993979D0 (no
Inventor
Egon Novak
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NO993979D0 publication Critical patent/NO993979D0/no
Publication of NO993979L publication Critical patent/NO993979L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO993979A 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor NO993979L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (fr) 1997-12-18 1998-12-18 Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet

Publications (2)

Publication Number Publication Date
NO993979D0 NO993979D0 (no) 1999-08-18
NO993979L true NO993979L (no) 1999-10-13

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993979A NO993979L (no) 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Country Status (18)

Country Link
US (1) US5985936A (fr)
EP (1) EP0967982A2 (fr)
CN (1) CN1252724A (fr)
AU (1) AU1656099A (fr)
BG (1) BG103740A (fr)
BR (1) BR9807577A (fr)
CA (1) CA2281710A1 (fr)
EE (1) EE9900354A (fr)
GE (1) GEP20022783B (fr)
HU (1) HUP0100737A3 (fr)
LT (1) LT4801B (fr)
LV (1) LV12438B (fr)
MD (1) MD1920F2 (fr)
NO (1) NO993979L (fr)
PL (1) PL335421A1 (fr)
RU (1) RU2173151C2 (fr)
SK (1) SK112999A3 (fr)
WO (1) WO1999032097A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AU2001253294A1 (en) 2000-04-14 2001-10-30 Mars, Incorporated Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
EP1601668B1 (fr) 2003-03-07 2008-08-27 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
CA2517573C (fr) * 2003-03-07 2011-12-06 Schering Corporation Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
AU2005208566A1 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. APOE genetic markers associated with age of onset of Alzheimer's Disease
WO2006068768A2 (fr) * 2004-11-24 2006-06-29 Hanna Skubatch Methodes et compositions pour traiter des troubles
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
CA2719749A1 (fr) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Procedes pour traiter des troubles utilisant un antagoniste selectif de sous-type nr2b de nmda
WO2010104375A1 (fr) 2009-03-12 2010-09-16 N.V. Nutricia Stigmastérol pour le traitement de la maladie d'alzheimer
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123617A1 (fr) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Procédé pour réduire l'expression du gène bcl2
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
RU2758376C2 (ru) 2017-09-14 2021-10-28 Феникс Байотекнолоджи, Инк. Способ и улучшенная нейропротекторная композиция для лечения неврологических патологических состояний
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
US20230263809A1 (en) 2019-12-24 2023-08-24 Folium Biosciences Europe B.V. Food supplement for alzheimer
EP3842039A1 (fr) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Complément alimentaire comprenant des cannbinoïdes et des phytostérols pour la maladie d'alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
BR9509119A (pt) * 1994-09-29 1997-10-28 Univ British Columbia Processo para o isolamento de uma composição de fitoesteróis a partir de um sabão de polpa composição diminuidora de colesterol e produto terapeuticamente eficaz para prevenir ou tratar aterosclerose ou dislipidemias primárias ou secundárias
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
ATE359071T1 (de) * 1997-05-15 2007-05-15 Univ Washington Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen

Also Published As

Publication number Publication date
SK112999A3 (en) 2001-11-06
AU1656099A (en) 1999-07-12
WO1999032097A3 (fr) 1999-09-02
US5985936A (en) 1999-11-16
EE9900354A (et) 2000-02-15
LT4801B (lt) 2001-06-25
PL335421A1 (en) 2000-04-25
BR9807577A (pt) 2001-08-07
NO993979D0 (no) 1999-08-18
EP0967982A2 (fr) 2000-01-05
GEP20022783B (en) 2002-09-25
HUP0100737A3 (en) 2002-07-29
LV12438B (en) 2000-09-20
BG103740A (en) 2000-05-31
LT99114A (lt) 2001-01-25
RU2173151C2 (ru) 2001-09-10
WO1999032097A2 (fr) 1999-07-01
CA2281710A1 (fr) 1999-07-01
CN1252724A (zh) 2000-05-10
MD1920F2 (ro) 2002-05-31
HUP0100737A2 (hu) 2001-09-28
MD990262A (en) 2000-06-30
LV12438A (en) 2000-03-20

Similar Documents

Publication Publication Date Title
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
PT1213015E (pt) Composicao farmaceutica oral com libertacao retardada de inibidores da bomba de protoes
DK1165537T3 (da) Hydroxymatairesinol til forebyggelse af cancer
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
NO2007004I1 (no) Mycofenolsyre = (E)-6-(1,3-dihydro-4-hydroksy-6-metoksy-7-metyl-3-oksajsobenzofuran-5-yl)-4-, metylheks-4-ensyre
BR9713866A (pt) Composição farmacéutica
DE68912237T2 (de) Dampfsensitive Zusammensetzung sowie diese enthaltende sterilisierungsanzeigende Zusammensetzung.
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
BR9814923A (pt) Método para tratamento de doença de alzheimer
PT998287E (pt) Utilizacao de levobupivacaina
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
AU4830097A (en) Use of an extract of Cimicifuga
FR2818148B1 (fr) Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
WO2002072021A3 (fr) Agents et procedes pour la prevention de l'apparition initiale ou de la recurrence des cancers existants
BR9506389B1 (pt) composto de silìcio, e, composição dietética, cosmética e terapêutica.
WO2000030425A3 (fr) Methode d'utilisation de la paraoxonase-1 pour reduire la formation d'atherome
DK1227826T3 (da) Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf
NO985695L (no) Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt
DE29511436U1 (de) Sitzmöbel, sowie Bausatz hierfür
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application